Tacrolimus: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz (New page: '''Tacrolimus''' is a "macrolide isolated from the culture broth of a strain of ''Streptomyces tsukubaensis'' that has strong immunosuppressive activity ''in vivo'' and prevents the ac...) |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
'''Tacrolimus''' is a "[[macrolide]] isolated from the culture broth of a strain of ''Streptomyces tsukubaensis'' that has strong immunosuppressive activity ''in vivo'' and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation ''in vitro''."<ref>{{MeSH}}</ref> It is a [[calcineurin]] inhibitor. Originally used as an antirejection drug in organ transplantation, it has been found useful in other medicial applications.<ref>{{citation | '''Tacrolimus''' is a "[[macrolide]] isolated from the culture broth of a strain of ''Streptomyces tsukubaensis'' that has strong immunosuppressive activity ''in vivo'' and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation ''in vitro''."<ref>{{MeSH}}</ref> It is a [[calcineurin]] inhibitor. Originally used as an antirejection drug in organ transplantation, it has been found useful in other medicial applications.<ref>{{citation | ||
| url = http://www.medscape.com/druginfo/monograph?cid=med&drugid=78369&drugname=Tacrolimus+Anhydrous+(Bulk)+Misc&monotype=monograph&monographid=395035&secid=3 | | url = http://www.medscape.com/druginfo/monograph?cid=med&drugid=78369&drugname=Tacrolimus+Anhydrous+(Bulk)+Misc&monotype=monograph&monographid=395035&secid=3 | ||
| Line 25: | Line 26: | ||
*the skin lesions of [[dermatomyositis]], [[vitiligo]], steroid-induced [[rosacea]], [[alopecia areata]]; and [[seborrheic dermatitis]]. | *the skin lesions of [[dermatomyositis]], [[vitiligo]], steroid-induced [[rosacea]], [[alopecia areata]]; and [[seborrheic dermatitis]]. | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
Latest revision as of 16:46, 5 February 2009
Tacrolimus is a "macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro."[1] It is a calcineurin inhibitor. Originally used as an antirejection drug in organ transplantation, it has been found useful in other medicial applications.[2]
Approved indications include therapy for Crohn's disease, and, in drug-eluting stents, as a means of preventing reocclusion after blood vessel revascularization. In topical form, it has been approved for atopic dermatitis.
Tacrolimus, and the related pimecrolimus, have also been employed for a number of off-label uses:[3]
- Cutaneous lupus erythematosus
- Netherton syndrome
- Psoriasis
- Lichen sclerosus
- perioral dermatitis
- the skin lesions of dermatomyositis, vitiligo, steroid-induced rosacea, alopecia areata; and seborrheic dermatitis.
References
- ↑ Anonymous (2024), Tacrolimus (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ American Society of Health-System Pharmacists, "Tacrolimus - Monograph", Medscape Drug Reference
- ↑ Bruce Jancin (February 2005), "Tacrolimus, Pimecrolimus Eyed for Off-Label Uses", Skin & Allergy News 36 (2): 22, DOI:10.1016/S0037-6337(05)70555-6